FAST: a Phase III trial of an anti-CLDN18.2 antibody GEJ adenocarcinoma

Salah-Eddin Al-Batran

Press brief by Salah-Eddin Al-Batran, MD of the Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

Share this video  
Similar topics
Gastrointestinal Cancer
FAST
ASCO 2016
Press Brief
3rd June 2016
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJOncology is intended for healthcare professionals